Related Experiment Videos
Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors
Brad O Buckman1, Yuo-Ling Chou, Meg McCarrick
1Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA. brad_buckman@berlex.com
Bioorganic & Medicinal Chemistry Letters
|April 20, 2005
Summary
Researchers developed novel aryl amidine inhibitors targeting Factor VIIa/Tissue Factor (FVIIa/TF) for potential therapeutic use. These potent small molecules show promise in modulating the coagulation cascade, offering new avenues for treating related disorders.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pharmacology
Background:
- The coagulation cascade is a complex system of serine proteases crucial for hemostasis.
- Factor VIIa/Tissue Factor (FVIIa/TF) plays a key role in initiating the extrinsic pathway of coagulation.
- Developing targeted inhibitors for FVIIa/TF is a significant therapeutic goal.
Purpose of the Study:
- To synthesize and characterize novel aryl amidine compounds.
- To identify potent small molecule inhibitors of FVIIa/TF.
- To evaluate the inhibitory activity of these compounds against other serine proteases in the coagulation cascade.
Main Methods:
- Combinatorial synthesis of polymer-linked formyl aryl amidines.
- Reductive amination and acylation for library generation.
- Enzyme inhibition assays to determine inhibitory constants (Ki) against FVIIa/TF and related proteases.
Main Results:
- Successful generation of aryl amidine libraries (compounds 8-13).
- Discovery of potent naphthylamidine inhibitors (compound 12) with Ki < 100 nM against FVIIa/TF.
- Characterization of inhibitory activity against other serine proteases within the coagulation cascade.
Conclusions:
- Novel aryl amidines, particularly naphthylamidines, are potent inhibitors of FVIIa/TF.
- These compounds represent promising leads for anticoagulant therapies.
- Further investigation into their selectivity and in vivo efficacy is warranted.